Adverse Reactions/Side Effects The following important adverse reactions are described below and elsewhere in the labeling: Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precautions (5.1)] Volume Depletion [see Warnings and Precautions (5.2)] Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fourniers Gangrene), and Genital Mycotic Infections [see Warnings and Precautions (5.3)] Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues [see Warnings and Precautions (5.4)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice
If binge eating does not improve within 3-6 months, or if concerning side effects or new eating disorder symptoms emerge, discontinuation should be seriously considered
Dose escalation, timing relative to large meals, existing reflux disease, and vagal or diabetic neuropathy each affect the strength with which gut signals reach the brainstem
do not freeze the reconstituted solution and avoid shaking
Do not ingest, inject, reconstitute, or otherwise administer
